ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc (MIRM)

42.65
0.26
(0.61%)
終了 12月18日 6:00AM
42.65
0.02
(0.05%)
取引時間後: 9:45AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
42.65
買値
41.50
売値
46.52
出来高
279,097
41.58 日の範囲 42.845
23.14 52 週間の範囲 48.89
時価総額
前日終値
42.39
始値
41.85
最終取引時間
財務取引量
US$ 11,820,926
VWAP
42.3542
平均取引量 (3 か月)
360,792
発行済株式数
48,004,582
配当利回り
-
PER
-12.52
1 株当たり利益 (EPS)
-3.4
歳入
186.37M
純利益
-163.42M

Mirum Pharmaceuticals Inc について

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
本社
Dover, Delaware, USA
設立
-
Mirum Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker MIRM. The last closing price for Mirum Pharmaceuticals was US$42.39. Over the last year, Mirum Pharmaceuticals shares have traded in a share price range of US$ 23.14 to US$ 48.89.

Mirum Pharmaceuticals currently has 48,004,582 shares in issue. The market capitalisation of Mirum Pharmaceuticals is US$2.03 billion. Mirum Pharmaceuticals has a price to earnings ratio (PE ratio) of -12.52.

MIRM 最新ニュース

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of...

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

- Late-breaker presentation to feature data from VANTAGE study evaluating volixibat in primary biliary cholangitis Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present...

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 8, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the...

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.49-1.1358368103843.1445.0341.648262443.06527279CS
41.132.7215799614641.5247.0841.050436537544.02916858CS
123.629.2749167307239.0348.8937.5136079241.82738998CS
2615.0554.528985507227.648.8927.153141839.07929118CS
5215.2855.827548410727.3748.8923.1455017932.87823478CS
15627.84187.98109385614.8148.8914.6344001228.38566582CS
26025.31145.96309111917.3448.899.1431723926.69862402CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
NUKKNukkleus Inc
US$ 11.655
(738.49%)
174.4M
PRTGPortage Biotech Inc
US$ 8.8678
(172.86%)
36.61M
OPTXSyntec Optics Holdings Inc
US$ 3.55
(99.44%)
93.16M
PTPIPetros Pharmaceuticals Inc
US$ 0.4976
(86.37%)
63.49M
LUXHLuxUrban Hotels Inc
US$ 0.849899
(59.67%)
29.52M
VCNXVaccinex Inc
US$ 1.41
(-61.37%)
758.95k
TNYATenaya Therapeutics Inc
US$ 1.395
(-51.56%)
42.45M
ORKTOrangeKloud Technology Inc
US$ 2.14
(-41.85%)
2.29M
RVPHReviva Pharmaceuticals Holdings Inc
US$ 1.395
(-39.35%)
18.16M
DBGIDigital Brands Group Inc
US$ 2.46
(-37.88%)
805.23k
RIMEAlgorhythm Holdings Inc
US$ 0.0877
(8.27%)
1.13B
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.335
(-36.79%)
1B
GOEVCanoo Inc
US$ 0.118
(7.08%)
382.65M
NVDANVIDIA Corporation
US$ 130.39
(-1.22%)
251.71M
XTIAXTI Aerospace Inc
US$ 0.0442
(8.33%)
221.41M